Cells are infused into a vein and travel the whole body.
A session delivers 50 or 100 million mesenchymal stem cells by intravenous infusion over 60 to 90 minutes. In circulation, the cells secrete immunomodulatory signals that act on chronic low-grade inflammation — the "inflammaging" that drives much of what adults feel as aging, explained in depth in the journal's cellular-aging article.
A physician prescribes the dose from your baseline biomarker panel, and follow-up labs at 3, 6, and 12 months measure the response.
We offer three systemic protocols.
Every vitality protocol starts from a baseline biomarker panel and is re-measured on schedule. The physician sets dose, route, and frequency individually for each patient.
IV Systemic MSC Infusion
Wharton's jelly umbilical-cord MSCs delivered intravenously to support systemic homing to sites of inflammation throughout the body. The core of most vitality protocols.
UC‑MSC 50M anti‑inflammatory · 100M high doseMuse Cell IV
A multilineage-differentiating subset within the MSC population, with stress-tolerance and homing characteristics that distinguish it from conventional MSCs. Standalone or as an upgrade.
Muse 1.5×10⁷ standard · 3.0×10⁷ high doseExosome & Combination
The cell-free extracellular-vesicle fraction, systemic — as an adjunct, or where whole-cell infusion is not appropriate. IV UC-MSC can be paired with intra-articular injections at the same visit for concurrent joint OA.
Exosome systemic · UC‑MSC + articular combosDoses run from 50 to 100 million cells.
Every dose is expanded from Wharton's jelly umbilical-cord tissue, tested for viability, and calibrated to your baseline labs.
50M
cells — the anti-inflammatory IV dose most vitality protocols are built around, infused over 60 to 90 minutes in a private suite.
100M
cells — the high-dose systemic protocol, prescribed when the physician's review of your baseline markers supports it.
ISO‑certified
GMP laboratory. Each dose is released only after sterility, identity, and viability verification.
What happens in circulation.
Tap a step to follow the cells through the bloodstream.
What the response looks like.
A typical systemic-protocol timeline. Subjective reports are noted along the way, and follow-up labs at month three measure the response.
Day 0
Infusion day
60 to 90 minutes in a private suite. Most patients notice nothing remarkable during or after; hydration and rest are the only requirements that evening.
First 72 hours
Mild effects, if any
Some report mild fatigue or a transient low-grade flush in the first 24 hours; both resolve without intervention.
Weeks 1–6
Early subjective window
When improvements appear, they tend to surface here: sleep quality, exercise recovery, morning stiffness, steadier energy. These are subjective reports; the clinical endpoints are the follow-up labs.
Months 3–6
Re-measurement
Follow-up labs repeat your inflammatory markers and functional measures, and the physician adjusts the protocol based on the results.
The evidence, briefly.
Three anchor findings from the peer-reviewed literature on systemic MSC therapy in aging.
Phase II
Randomized, double-blind, placebo-controlled: allogeneic MSCs improved physical performance, inflammatory biomarkers (TNF-α), and quality of life in aging frailty at six months.
Tompkins BA, et al. J Gerontol A Biol Sci Med Sci, 2017.
Meta‑analysis
Updated systematic review: intravascular MSC administration continues to appear safe, with adverse events typically mild, transient, and self-limited.
Thompson M, et al. EClinicalMedicine, 2020.
Mechanism
The MSC as "injury drugstore": the cells act chiefly through secreted immunomodulatory and trophic signals, not tissue replacement.
Caplan AI, Correa D. Cell Stem Cell, 2011.
The evidence base for systemic regenerative therapy in healthy-aging applications is earlier-stage than for joint osteoarthritis, and none of it guarantees a result for any individual. We will not tell you we can extend your lifespan. These protocols do not substitute for the foundations of healthy aging — sleep, resistance training, protein adequacy, lipid management, stress regulation — and will not reverse a chronic disease that has not been independently treated. Not FDA-approved for these uses; provided in México under COFEPRIS after individual physician review of your baseline biomarkers and history.
